Dr. Hossein Borghaei on Selecting Checkpoint Inhibitors in NSCLC

Video

Hossein Borghaei, DO, associate professor at Fox Chase Cancer Center, discusses selecting between nivolumab (Opdivo) and pembrolizumab (Keytruda) in second-line non–small cell lung cancer (NSCLC).

Hossein Borghaei, DO, associate professor at Fox Chase Cancer Center, discusses selecting between nivolumab (Opdivo) and pembrolizumab

(Keytruda) in second-line non—small cell lung cancer (NSCLC).

There is no head-to-head comparison of 1 agent versus the other, said Borghaei, so all oncologists have to go on are the clinical data from separate clinical trials. It is always difficult to do cross-trial comparisons, he said.

Scheduling is a factor in decision making, as nivolumab is given every 2 weeks versus pembrolizumab which is given every three weeks.

From a clinical decision-making process, most patients who are now in second-line, as long as they have reasonable performance status and can withstand any potential toxicity that could arise, would be candidates for treatment with either of these agents, said Borghaei.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD